A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT06089616
·
clinicaltrials.gov ↗
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Fibrodysplasia Ossificans Progressiva
Sponsor
Ipsen